Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Passage Bio, Inc. before investing.

In this article, we go over a few key elements for understanding Passage Bio, Inc.’s stock price such as:

• Passage Bio, Inc.’s current stock price and volume
• Why Passage Bio, Inc.’s stock price changed recently
• Upgrades and downgrades for PASG from analysts
• PASG’s stock price momentum as measured by its relative strength

About Passage Bio, Inc. (PASG)

Before we jump into Passage Bio, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Want to learn more about Passage Bio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Passage Bio, Inc..

Passage Bio, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Passage Bio, Inc.’s stock price was $4.470.

Passage Bio, Inc. is down 0.45% from its previous closing price of $4.490.

During the last market session, Passage Bio, Inc.’s stock traded between $4.470 and $4.620. Currently, there are approximately 3.21 million shares outstanding for Passage Bio, Inc..

Passage Bio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Passage Bio, Inc. Stock Price History

Passage Bio, Inc.’s (PASG) price is currently down 8.4% so far this month.

During the month of July, Passage Bio, Inc.’s stock price has reached a high of $5.060 and a low of $4.250.

Over the last year, Passage Bio, Inc. has hit prices as high as $20.000 and as low as $3.290. Year to date, Passage Bio, Inc.’s stock is down 62.12%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Passage Bio, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 31, 2026,, no analysts have changed their rating of Passage Bio, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Passage Bio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Passage Bio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Passage Bio, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Passage Bio, Inc. (PASG) by visiting AAII Stock Evaluator.

Relative Price Strength of Passage Bio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Passage Bio, Inc. has a weighted four-quarter relative price strength of -4.95%, which translates to a Momentum Score of 36 and is considered to be Weak.

Want to learn more about how Passage Bio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Passage Bio, Inc. Stock Price: Bottom Line

As of July 31, 2026, Passage Bio, Inc.’s stock price is $4.470, which is down 0.45% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Passage Bio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.